^
Association details:
| Biomarker: | PD-L2 overexpression |
|---|---|
| Cancer: | Colorectal Adenocarcinoma |
| Drug Class: | PD-L1 inhibitor + PD-L2 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Published date:
05/01/2019
Excerpt:
The PD-L2–overexpressing cell lines MC-38 (MC-38-L2) and CT26-NY-ESO-1 (CT26-NY-ESO-1-L2) were thus developed to evaluate influence of PD-L2...MC-38-L2 cells (1.0 × 106) were injected subcutaneously on day 0, and ICB treatments as indicated were started on days 3, 6, and 9….The combination of anti-PD-L1 mAb and anti-PD-L2 mAb showed a comparable tumor growth inhibition in PD-L2–expressing tumor growth as observed by anti-PD-1 mAb...
DOI:
10.1158/1078-0432.CCR-18-3991
